The economic implications of treating atherothrombotic disease in australia, from the government perspective

Ademi, Zanfina; Liew, Danny; Hollingsworth, Bruce; Wolfe, Rory; Steg, Gabriel; Bhatt, Deepak L.; Reid, Christopher M.

doi:10.1016/j.clinthera.2010.01.009

Cited by 19 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with other reports, [3][4][5][6]14,[16][17][18]23 PAD was associated with a high rate of health care utilization and cost. Notably, patients with PAD had approximately twice as many outpatient visits per year (approximately 10 additional visits) in the first year after diagnosis than did patients without PAD.…”

Section: Discussionsupporting

confidence: 92%

“…13 The prevalence of PAD increases with age, and previous studies have found high clinical and economic burden on the elderly associated with the disease. [4][5][6][14][15][16][17][18] Meanwhile, the effect of PAD among young and middle-aged adults can be significant, because these patients need long-term medical care, and the disease can lead to the loss of productivity. However, no previous study has examined the prognosis and the associated health care cost of PAD in a relatively young working population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Economic Burden in Patients with Diagnosis of Peripheral Arterial Disease in a Claims Database in Japan

Hosaka¹,

Miyata²,

Onishi³

et al. 2014

Clinical Therapeutics

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Clinical and Economic Burden in Patients with Diagnosis of Peripheral Arterial Disease in a Claims Database in Japan

Hosaka¹,

Miyata²,

Onishi³

et al. 2014

Clinical Therapeutics

View full text Add to dashboard Cite

“…In addition, few of the existing cardiovascular registries report the cost of illness and cost effectiveness of treatment in real world settings [11][12][13][14]. This information is important as the frequency of resource utilization among subjects in outpatient settings differs markedly from those in acute hospital care [15].…”

Section: Introductionmentioning

confidence: 99%

Is It Cost‐Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Ademi

Liew

Hollingsworth

et al. 2011

Cardiovascular Therapeutics

Self Cite

View full text Add to dashboard Cite

SUMMARYAims: To describe aspirin use in primary and secondary prevention and to determine the incremental costs-effectiveness ratio (ICER) per life year gain (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic disease. Design and Subjects: To project the cost-effectiveness of aspirin over 5 years of follow-up, a Markov state transition model was developed with yearly cycles and the following health states: "Alive" (post-CAD) and "Dead." The model compared current coverage observed among 2361 subjects using the prospective Australian subset of Reduction of Atherothrombosis for continued Health (REACH) registry, and hypothetical situation whereby all subjects assumed to be treated. Costs were calculated based on the Australian government reimbursed data for 2010. Main outcome measures: ICER per LYG for increased use of aspirin. Results: The use of aspirin in current group varied from 67% to 70%. The base-case analysis showed that increasing aspirin use among subjects with existing CAD in outpatient settings was cost saving, while increasing use of aspirin in primary prevention equated to an ICER of AUD 7126 per LYG. Conclusion: Among subjects with existing CAD aspirin use was shown to be a dominant choice of treatment. However, among patients without existing cardiovascular disease (primary prevention), increased uptake of aspirin was cost effective but with uncertain benefit, with two hemorrhagic bleeding events occurring for every life saved.

show abstract

“…Peripheral arterial disease, as an atherothrombotic disease, contributes to the number one killer of all Australians (Ademi et al, 2010). While existing guidelines recommend supervised exercise and strict risk factor reduction for the management of PAD, nurse-led intervention programs which provide the opportunity to do both remain scarce and underutilised in Australia.…”

Section: Resultsmentioning

confidence: 99%

“…Atherothrombotic disease, which encompasses coronary artery disease, ischemic stroke and PAD, is the most common cause of morbidity and mortality worldwide and as such carries great economic burden (Ademi et al, 2010) (Watkins, 2004). and economic burden of PAD in the aging population (Mahoney et al, 2008).…”

Section: The Increasing Cost Of Padmentioning

confidence: 99%

Can a nurse-led intervention program for people with peripheral arterial disease lead to sustained improvement in functional capacity and quality of life?

McLennan¹

View full text Add to dashboard Cite

Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis which causes significant morbidity and mortality affecting between 14% and 29% of individuals >70 years of age . Multiple studies have demonstrated an improvement in walking distance in people suffering from symptomatic PAD through exercise therapy. While most studies have examined the results of exercise and risk factor modification programs over a short-term this study sought to identify not only whether a nurse-led intervention program can improve functional capacity and quality of life, but if improvements could be sustained over a longer follow-up term. After a mean follow up time of 52 months, the NLIP group had sustained a 14% mortality rate. This is in keeping with the 5-year predicted mortality found amongst PAD sufferers. 3The results from this study suggest that a nurse-led intervention program for people with PAD can have sustained improvement in pain free walking distance and emotional well-being. Further research is required to identify whether earlier intervention may lead to a reduction in mortality rates in PAD population.4

show abstract

The economic implications of treating atherothrombotic disease in australia, from the government perspective

Cited by 19 publications

References 21 publications

Clinical and Economic Burden in Patients with Diagnosis of Peripheral Arterial Disease in a Claims Database in Japan

Clinical and Economic Burden in Patients with Diagnosis of Peripheral Arterial Disease in a Claims Database in Japan

Is It Cost‐Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Can a nurse-led intervention program for people with peripheral arterial disease lead to sustained improvement in functional capacity and quality of life?

Contact Info

Product

Resources

About